Ventrus Biosciences (VTUS) says two clinical dermal safety studies of VEN 307 demonstrate the treatment is safe and well tolerated.
No serious AE's were reported.
All pharmacokinetic parameters were met in a separate study, consistent with an earlier investigator sponsored trial.
The data "mark another important step in [the] effort to develop and commercialize [the drug]," CEO Russell Ellison says.
VEN 307 is currently in a second pivotal Phase 3 trial. (PR)
Shares +12% premarket.